Rafael Holdings, Inc. Appoints Mimi Huizinga as Chief Development and Medical Officer, Effective October 18, 2021
October 06, 2021 at 04:00 pm IST
Share
Rafael Holdings, Inc. announced the appointment of Mary Margaret (Mimi) Huizinga as Chief Development and Medical Officer, effective October 18, 2021. Dr. Huizinga recently served as the Head of US Oncology Medical for Novartis, overseeing the clinical development and medical affairs activities of the Novartis oncology portfolio in the US. Before leading the medical function, Dr. Huizinga built and led the strategic data and digital function in the US Oncology business unit at Novartis. The strategic data and digital function included real-world evidence, healthcare economics and clinical and value evidence liaisons in addition to supporting digital marketing and constructing a data strategy and platform. During her time at Novartis, Dr. Huizinga participated in more than a dozen product and indication launches. Prior to Novartis, she was the Chief Health Information Officer at Premier, Inc, where she also led the Applied Sciences division partnering with several pharmaceutical companies around evidence generation needs. Dr. Huizinga has previously served as the VP of Quality at Lifepoint Health, an associate at McKinsey & Company and an Associate Professor at Johns Hopkins University. Dr. Huizinga holds an MD and MPH from Vanderbilt University and is a fellow of the American College of Physicians.
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. The Company's segments include healthcare and real estate. The Company's investments include Cornerstone Pharmaceuticals, Inc., which is a cancer metabolism-based therapeutics company; LipoMedix Pharmaceuticals Ltd., which is a clinical-stage pharmaceutical company; Barer Institute Inc., which is a preclinical cancer metabolism research operation; Cyclo Therapeutics Inc., which is a clinical-stage biotechnology company dedicated to developing medicines for patients and families living with diseases through its therapeutic asset like Trappsol and Cyclo; Day Three Labs, Inc., which offers pharmaceutical-grade technology like Unlokt, and Rafael Medical Devices, LLC, which is an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. Its real estate segment comprises of a portion of a commercial building in Israel.